Advertisement

Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer

  • Ilya PokataevEmail author
  • Asel Kudaibergenova
  • Anna Artemyeva
  • Anna Popova
  • Alexey Rumyantsev
  • Danil Podluzhny
  • Nikolay Kudashkin
  • Mikhail Fedyanin
  • Alexey Tryakin
  • Sergey Tjulandin
Original Research
  • 42 Downloads

Abstract

Background

The aim of our study was to evaluate consistency of SMAD4 expression in different tumor areas and its correlation with recurrence pattern in patients after resection for pancreatic cancer (PC).

Methods

Records of patients who underwent resection for nonmetastatic PC between 2001 and 2015 were analyzed. Formalin-fixed, paraffin-embedded tissue sections from different areas of primary tumor and lymph node metastases were analyzed immunohistochemically (IHC) for SMAD4 expression using TMA technology.

Results

SMAD4 expression was assessed in 356 tissue sections obtained from 91 patients. SMAD4 expression was positive in all assessed tumor slides only in 7 of 26 patients (26.9%). There were 54 recurrences (9 locoregional, 41 distant, and 4 both local and distant) with median follow-up of 21.7 months. There was no correlation between SMAD4 expression and locoregional recurrence pattern (p = 0.30). SMAD4 status influenced neither distant recurrence-free survival (p = 0.99) nor overall survival (p = 0.13).

Conclusions

Different areas inside primary tumor and lymph node metastases express SMAD4 heterogeneously. SMAD4 IHC expression is not a biomarker of the recurrence pattern after surgical resection for PC.

Keywords

Pancreatic neoplasms Smad4 protein Recurrence pattern 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Financial Support

The study was funded by N.N. Blokhin Russian Cancer Research Center. No other support was done.

References

  1. 1.
    Neoptolemos JP, Palmer DH, Ghaneh P, Ghaneh P, Psarelli EE, Valle JW, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.CrossRefPubMedGoogle Scholar
  3. 3.
    Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Supplement 5):v56–68.CrossRefPubMedGoogle Scholar
  4. 4.
    Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, et al. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006;66:2202–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29:3037–43.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806–13.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chen W, Foran DJ. Advances in cancer tissue microarray technology: towards improved understanding and diagnostics. Anal Chim Acta. 2006;564(1):74–81.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Goodman LA, Kruskal WH. Measures of association for cross classifications. Part I. J Am Stat Assoc. 1954;49:732–64.Google Scholar
  10. 10.
    Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–88.CrossRefPubMedGoogle Scholar
  11. 11.
    Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 1999;230:776–84.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Van Laethem J, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450–6.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30:4077–83.CrossRefPubMedGoogle Scholar
  14. 14.
    Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Wash. DC). 1996;271:350–3.CrossRefGoogle Scholar
  15. 15.
    Winter JM, Tang LH, Klimstra DS, Liu W, Linkov I, Brennan MF, et al. Failure patterns in resected pancreas adenocarcinoma. Lack of predicted benefit to SMAD4 expression. Ann Surg. 2013;258:331–5.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Shin SH, Kim HJ, Hwang DW, Lee JH, Song KB, Jun E, et al. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: a prospective cohort study. Oncotarget. 2017;8:17945–59.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Toga T, Nio Y, Hashimoto K, Higami T, Maruyama R. The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome. Anticancer Res. 2004;24(2C):1173–8.PubMedGoogle Scholar
  18. 18.
    Shugang X, Hongfa Y, Jianpeng LXZ, Jingqi F, Xiangxiang L, et al. Prognostic value of SMAD4 in pancreatic cancer: a meta-analysis. Transl Oncol. 2016;9(1):1–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ilya Pokataev
    • 1
    Email author
  • Asel Kudaibergenova
    • 2
  • Anna Artemyeva
    • 3
  • Anna Popova
    • 1
  • Alexey Rumyantsev
    • 1
  • Danil Podluzhny
    • 4
  • Nikolay Kudashkin
    • 4
  • Mikhail Fedyanin
    • 1
  • Alexey Tryakin
    • 1
  • Sergey Tjulandin
    • 1
  1. 1.Department of Clinical Pharmacology and ChemotherapyFederal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian FederationMoscowRussia
  2. 2.Department of CytologyFederal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian FederationMoscowRussia
  3. 3.Department of PathologyN.N. Petrov Cancer Research InstituteSaint PetersburgRussia
  4. 4.Department of Surgery #7Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian FederationMoscowRussia

Personalised recommendations